Parisa Yousefpour

Parisa Yousefpour

Auto-generated profile, based on publicly available information

Parisa Yousefpour

Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 June 2025 in Science Translational Medicine
Verified
Journal Article
Open access
KRKristen A. Rodrigues
Kristen A. Rodrigues
YZYiming J. Zhang
Yiming J. Zhang
JLJonathan Lam
Jonathan Lam
AAAereas Aung
Aereas Aung
DMDuncan M. Morgan
Duncan M. Morgan
DIDarrell J. Irvine
Darrell J. Irvine
Vaccine adjuvants play important roles in shaping the humoral response to immunization. Here, we analyzed mechanisms of action of a clinically relevant combination adjuvant strategy, where phosphoserine (pSer)–tagged immunogens bound to aluminum hydroxide (alum) adjuvant, promoting prolonged antigen release to draining lymph nodes, are combined with a saponin nanoparticle adjuvant termed SMNP, which alters lymph flow and antigen entry into lymph nodes. When used with a stabilized HIV envelope trimer antigen in mice, this combined adjuvant approach promoted substantial enhancements in germinal center and antibody responses relative to either adjuvant alone. Using single-cell RNA and B cell receptor sequencing, we found that the alum-pSer/SMNP combination augmented the clonal expansion and diversity of the germinal center B cell repertoire, coincident with an increased proportion of S-phase germinal center B cells and expression of positive selection markers. Moreover, we found that the combination adjuvant approach, but not alum-pSer delivery or SMNP alone, promoted accumulation of intact antigen on follicular dendritic cells, reflecting integrated effects of slow antigen delivery and altered lymph node uptake. Genetic ablation of Cr1/2 expression by follicular dendritic cells eliminated antigen accumulation and hampered the antigen-specific germinal center response, supporting antigen delivery to these cells as a key mechanism of the improved response elicited by this combination adjuvant. These results demonstrate how adjuvants with complementary mechanisms of action affecting vaccine biodistribution and kinetics can enhance humoral immunity.

25 November 2024 in PNAS Nexus
Verified
Journal Article
Open access
PDF file
PYParisa Yousefpour
Parisa Yousefpour
YZYiming J Zhang
Yiming J Zhang
LMLaura Maiorino
Laura Maiorino
MMMariane Bandeira Melo
Mariane Bandeira Melo
MRMariluz A Arainga Ramirez
Mariluz A Arainga Ramirez
DIDarrell J Irvine
Darrell J Irvine
Saponin-based vaccine adjuvants are potent in preclinical animal models and humans, but their mechanisms of action remain poorly understood. Here, using a stabilized HIV envelope trimer immunogen, we carried out studies in nonhuman primates (NHPs) comparing the most common clinical adjuvant aluminum hydroxide (alum) with saponin/monophosphoryl lipid A nanoparticles (SMNP), an immune-stimulating complex–like adjuvant. SMNP elicited substantially stronger humoral immune responses than alum, including 7-fold higher peak antigen-specific germinal center B-cell responses, 18-fold higher autologous neutralizing antibody titers, and higher levels of antigen-specific plasma and memory B cells. Positron emission tomography and computed tomography imaging in live NHPs showed that, unlike alum, SMNP promoted rapid antigen accumulation in both proximal and distal lymph nodes (LNs). SMNP also induced strong type I interferon transcriptional signatures, expansion of innate immune cells, and increased antigen-presenting cell activation in LNs. These findings indicate that SMNP promotes multiple facets of the early immune response relevant for enhanced immunity to vaccination.

28 August 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
PYParisa Yousefpour
Parisa Yousefpour
YZYiming J. Zhang
Yiming J. Zhang
LMLaura Maiorino
Laura Maiorino
MMMariane B. Melo
Mariane B. Melo
MRMariluz A. Arainga Ramirez
Mariluz A. Arainga Ramirez
DIDarrell J. Irvine
Darrell J. Irvine
SUMMARY: Saponin-based vaccine adjuvants are potent in preclinical animal models and humans, but their mechanisms of action remain poorly understood. Here, using a stabilized HIV envelope trimer immunogen, we carried out studies in non-human primates (NHPs) comparing the most common clinical adjuvant alum with Saponin/MPLA Nanoparticles (SMNP), a novel ISCOMs-like adjuvant. SMNP elicited substantially stronger humoral immune responses than alum, including 7-fold higher peak antigen-specific germinal center B cell responses, 18-fold higher autologous neutralizing antibody titers, and higher levels of antigen-specific plasma and memory B cells. PET-CT imaging in live NHPs showed that, unlike alum, SMNP promoted rapid antigen accumulation in both proximal and distal lymph nodes (LNs). SMNP also induced strong type I interferon transcriptional signatures, expansion of innate immune cells, and increased antigen presenting cell activation in LNs. These findings indicate that SMNP promotes multiple facets of the early immune response relevant for enhanced immunity to vaccination.

20 July 2020 in Advanced Therapeutics
Verified
Journal Article
Closed access
PDF file
PYParisa Yousefpour
Parisa Yousefpour
AVAnastasia Varanko
Anastasia Varanko
RSRishi Subrahmanyan
Rishi Subrahmanyan
ACAshutosh Chilkoti
Ashutosh Chilkoti